<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Anixa Biosciences and Cleveland Clinic Receive FDA Clearance for Clinical Trials of Breast Cancer Vaccine
Image Overlay - Anixa Biosciences and Cleveland Clinic Receive FDA Clearance for Clinical Trials of Breast Cancer Vaccine

Anixa Biosciences and Cleveland Clinic Receive FDA Clearance for Clinical Trials of Breast Cancer Vaccine

Anixa Biosciences and Cleveland Clinic Receive FDA Clearance for Clinical Trials of Breast Cancer Vaccine

Anixa Biosciences announced that the FDA has cleared the Investigational New Drug (IND) application for its breast cancer vaccine. The technology immunizes against the alpha-lactalbumin protein that is expressed in the mammary glands of women during lactation. After lactation, the protein is no longer expressed until a woman develops breast cancer. Researchers anticipate that the vaccine will support the immune system in destroying cancer cells before they have the opportunity to grow into a mature cancer. Yourway is looking forward to seeing the results of further trials and fully supports the fight against cancer.

Back to Index
Media

Upcoming Events

Clinical Trial Supply East Coast 2022

October 19-20, 2022
King of Prussia, PA, USA

Media

Articles

Helping Sponsors Navigate Complex Ancillary Supply Sourcing Challenges with Integrated Services

Open chat
Come chat with us!
Hello! How can I help you?